PF-562271 HCl: Advanced FAK/Pyk2 Inhibitor for Applied Cancer Research

Principle and Setup: Targeting FAK/Pyk2 Signaling with Precision

Focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) are pivotal non-receptor tyrosine kinases orchestrating cell adhesion, migration, and survival—processes fundamental to cancer metastasis and tumor microenvironment modulation. PF-562271 HCl is a potent, ATP-competitive, and reversible inhibitor developed to selectively target these kinases. With an IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, this compound exhibits approximately 10-fold selectivity for FAK versus Pyk2 and over 100-fold selectivity against most other kinases, ensuring high specificity in dissecting focal adhesion kinase signaling pathways. Its hydrochloride salt form, available from APExBIO, enhances handling and solubility, making it ideal for both in vitro and in vivo studies focused on cancer research and tumor growth inhibition.

PF-562271 HCl’s ability to inhibit FAK phosphorylation (EC₅₀ = 93 ng/mL in tumor-bearing mouse models) directly translates to suppression of tumor growth and metastasis. This makes it a cornerstone for studies investigating the mechanistic underpinnings of cancer progression, as highlighted in recent work on the role of circRHOBTB3 in metastatic prostate cancer (Song et al., 2025), where modulation of FAK and related signaling cascades is critical for delineating tumor suppressor pathways.

Workflow and Protocol Enhancements: Maximizing Experimental Reproducibility

Compound Handling and Preparation

• Solubility: PF-562271 HCl is highly soluble in DMSO at concentrations ≥26.35 mg/mL when gently warmed, but is insoluble in water and ethanol. Prepare concentrated stock solutions in DMSO for easy aliquoting.
• Storage: Store the solid form at -20°C. For solution stocks, avoid long-term storage; prepare fresh aliquots and use promptly to maintain potency and reproducibility.

Cell-Based Assays: Step-by-Step Workflow

1. Cell Line Selection: Choose cancer cell lines with high FAK/Pyk2 activity, such as PCa (prostate cancer) lines, for studies on proliferation, migration, or invasion.
2. Compound Dilution: Thaw DMSO stocks and dilute into culture media to achieve working concentrations (typically 1–500 nM). Ensure the final DMSO concentration does not exceed 0.1% to avoid cytotoxicity.
3. Treatment Timing: Incubate cells with PF-562271 HCl for 1–72 hours, depending on experimental endpoints (e.g., short-term phosphorylation assays vs. long-term proliferation or metastasis studies).
4. Readouts: Quantify FAK phosphorylation status via Western blot, immunofluorescence, or ELISA. Assess functional endpoints such as cell proliferation (MTT, XTT, EdU assays), migration (wound healing, transwell), or apoptosis (Annexin V/PI staining).

In Vivo Applications

• Dosing: In murine tumor models, PF-562271 HCl is typically administered at doses calibrated to achieve plasma concentrations above the EC₅₀ for FAK inhibition (e.g., 10–50 mg/kg, according to published protocols).
• Readouts: Monitor tumor volume, metastatic burden, and downstream signaling biomarkers (e.g., phosphorylated FAK, Pyk2, or related survival pathways).

For further protocol details and advanced workflow enhancements, the article "PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Cancer Research" provides actionable step-by-step guidance, which complements the setup outlined here.

Advanced Applications & Comparative Advantages

Dissecting Tumor Microenvironment Modulation

PF-562271 HCl’s robust selectivity and nanomolar potency make it uniquely suited for unraveling the crosstalk between tumor cells and their microenvironment. In studies such as Song et al. (2025, Cancer Letters), FAK/Pyk2 inhibition has been instrumental in probing how tumor-suppressive non-coding RNAs (e.g., circRHOBTB3) modulate cell proliferation and metastatic potential through kinase signaling axes. By reversing FAK-driven signaling, PF-562271 HCl enables direct analysis of downstream gene regulation, such as MAOA suppression, and provides a controlled platform for validating novel therapeutic targets or biomarkers.

Superior Selectivity and Workflow Compatibility

Compared to less selective kinase inhibitors, PF-562271 HCl demonstrates:

• 10-fold selectivity: for FAK over Pyk2, allowing nuanced analysis of kinase-specific roles.
• 100-fold selectivity: over most other kinases (except some CDKs), minimizing off-target effects and experimental noise.
• Reversible ATP-competitive inhibition: providing temporal control during washout or recovery experiments.

Its compatibility with high-throughput screening, cell-based phenotypic assays, and in vivo tumor models positions PF-562271 HCl as a gold-standard tool for translational research. As detailed in the article "PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Tumor Microenvironment Studies", this compound’s workflow-friendly solubility and reproducibility distinguish it from alternatives and extend its utility across diverse cancer models.

Comparative Extension and Research Ecosystem

The scenario-driven guide, "PF-562271 HCl (SKU A8345): Precision FAK/Pyk2 Inhibition", extends these insights by benchmarking PF-562271 HCl against other kinase inhibitors, highlighting best practices for maximizing reproducibility and sensitivity. Together, these resources form a cohesive ecosystem for applied cancer research, from mechanistic pathway dissection to preclinical drug development.

Troubleshooting and Optimization Tips

Solubility Challenges

• Problem: Poor solubility or precipitation in aqueous buffers.
• Solution: Always dissolve PF-562271 HCl in DMSO first; gently warm to facilitate dissolution. Dilute into pre-warmed media to avoid precipitation. Avoid water or ethanol as solvents.

Compound Stability and Storage

• Problem: Loss of activity due to repeated freeze-thaw cycles or prolonged storage in solution.
• Solution: Store solid at -20°C. Prepare fresh DMSO aliquots for each experiment. Do not store diluted solutions for extended periods.

Assay Sensitivity and Signal Window

• Problem: Insufficient inhibition of FAK/Pyk2 or high background signal.
• Solution: Titrate PF-562271 HCl across a nanomolar to low micromolar range; confirm pathway inhibition via direct readouts (e.g., p-FAK Western blot). Use serum-starved conditions to reduce basal kinase activation, increasing assay sensitivity.

Off-Target Effects and Selectivity Controls

• Problem: Observed phenotypes not attributable to FAK/Pyk2 inhibition.
• Solution: Include genetic controls (siRNA/shRNA knockdown of FAK or Pyk2) alongside chemical inhibition. Validate specificity using kinase activity panels if possible. Leverage PF-562271 HCl’s selectivity profile to interpret results confidently.

Workflow Reproducibility

• Best Practice: Use validated sources like APExBIO for consistent batch quality. Standardize experimental timing, dosing, and readout conditions.

Future Outlook: Integrating PF-562271 HCl into Next-Generation Oncology Research

As the molecular landscape of cancer becomes increasingly nuanced, tools like PF-562271 HCl are essential for advancing both basic and translational oncology. The emerging role of non-coding RNAs and their interaction with kinase signaling—exemplified by circRHOBTB3’s tumor-suppressive mechanism in Song et al. (2025)—highlights new therapeutic frontiers where reversible FAK/Pyk2 inhibitors can validate targets and accelerate drug discovery.

Future directions will see PF-562271 HCl applied in combination screens, immuno-oncology models, and precision medicine platforms. Its compatibility with high-throughput and omics-based workflows ensures relevance in systems biology and personalized therapy design. Ongoing enhancements in selectivity, formulation, and delivery will further extend its impact, cementing PF-562271 HCl as a linchpin for cutting-edge cancer research.

Ready to enhance your research? Learn more about PF-562271 HCl from APExBIO and integrate this advanced FAK/Pyk2 inhibitor into your experimental pipeline today.